公司资料
HOOKIPA Pharma Inc. 股价、新闻与催化剂
- 股票代码:
- HOOK
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
1.15 USD (+0.88%)
收盘价
最后更新: 2026年6月2日
—
市值
股价为何变动
目前无法获取 HOOK 的收盘价变动背景。
公司概览
Arenaviral Immunotherapy Platform
HOOKIPA Pharma develops immunotherapies using engineered arenavirus vectors designed to generate strong antigen-specific T-cell responses. The platform supports both oncology programs and partnered infectious-disease vaccines.
HB-700 for KRAS-Mutated Cancers
HB-700 is a multi-antigen therapy directed at common KRAS mutations across lung, colorectal, pancreatic, and other cancers. The program uses repeated administration of complementary vectors to sustain immune activity against tumor antigens.
Clinical Proof from Eseba-Vec
The HB-700 strategy is supported by clinical experience with eseba-vec, formerly HB-200, in HPV16-positive head and neck cancer. That program demonstrated the platform's ability to induce antigen-specific immune responses in patients with advanced cancer.
Partnered Infectious-Disease Programs
HOOKIPA has collaborated with Gilead on arenaviral immunotherapies for hepatitis B and HIV. Partner funding and milestone economics provide a second business model alongside internally led oncology development.
Portfolio Prioritization
The company has paused or divested selected programs to focus capital on its highest-priority assets and collaborations. Its development model relies on specialized vector engineering, outsourced manufacturing, and external clinical networks.
未来催化剂
- Interim Phase 1 data from HB-700 in KRAS-mutated cancers in the first half of 2026.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。